{'fraction_non_alphanumeric': 0.053691275167785234, 'fraction_numerical': 0.06711409395973154, 'mean_word_length': 4.472477064220183, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The Single Nucleotide Polymorphisms (rs1929992) in IL-33 is Associated with Gyneacological and Breast Cancer

The aim of the present study is to evaluate the role of Interleukin-33 gene polymorphism among patients with gyneacological and breast cancer. Blood samples were collected from 120 patients with gyneacological and breast cancer, and 79 healthy women were control group. rs1929992 (in IL-33 gene) were determined using PCR-RFLP. The statistical analysis and data presentation in the present study was based on inclusion of 120 women with cancer (uterine, breast, ovarian and cervical) serving as a study group and 79 apparently healthy women serving as a control group. The prevalence rate of homozygous wild genotype (A/A), related to IL-33, was 74.7% (59 out of 79) in control group and 49.2% (59 out of 120) in study group. In addition, the prevalence rate of heterozygous wild and recessive genotype (A/G), related to IL-33, was 15.2% (12 out of 79) in control group and 32.5% (39 out of 120) in study group. Moreover, the prevalence rate of homozygous recessive genotype (G/G), related to IL-33, was 10.1% (8 out of 79) in control group and 18.3% (22 out of 120) in study group.